Expression and function of vinculin in neuroendocrine tumors

Tumor Biology

Volumn 28, Issue 4, 2007, Pages 196-204

  Liu, Minghui ^a   Öberg, Kjell ^a   Zhou, Yinghua ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Claudin 4; Neuroendocrine tumor; siRNA; Tumor suppressor gene; Vasostatin; Vinculin

Indexed keywords

CLAUDIN 4; VINCULIN;

ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DISEASE COURSE; GROWTH REGULATION; HUMAN; HUMAN CELL; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 34548498893     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107415     Document Type: Article

References (25)

1. Liu M, Kilarski WW, Gerwins P, Oberg K, Zhou Y: Efficient human interferon-alpha gene transfer to neuroendocrine tumor cells with long-term and stable expression. Neuroendocrinology 2006;82:264-273.
2. Weis WI: Cell biology: how to build a cell junction. Nature 2004;430:513-515.
3. Rodriguez Fernandez JL, Geiger B, Salomon D, Sabanay I, Zoller M, Ben-Ze'ev A: Suppression of tumorigenicity in transformed cells after transfection with vinculin cDNA. J Cell Biol 1992;119:427-438.
4. Rodriguez Fernandez JL, Geiger B, Salomon D, Ben-Ze'ev A: Overexpression of vinculin suppresses cell motility in BALB/c 3T3 cells. Cell Motil Cytoskeleton 1992;22:127-134.
5. Coll JL, Ben-Ze'ev A, Ezzell RM, Rodriguez Fernandez JL, Baribault H, Oshima RG, Adamson ED: Targeted disruption of vinculin genes in F9 and embryonic stem cells changes cell morphology, adhesion, and locomotion. Proc Natl Acad Sci USA 1995;92:9161-9165.
6. Evers BM, Ishizuka J, Townsend CM Jr, Thompson JC: The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann NY Acad Sci 1994;733:393-406.
7. Cohen DM, Chen H, Johnson RP, Choudhury B, Craig SW: Two distinct head-tail interfaces cooperate to suppress activation of vinculin by talin. J Biol Chem 2005;280:17109-17117.
8. Zhou Y, Gobl A, Wang S, Jacobsen MB, Janson ET, Haines GK 3rd, Radosevich JA, Oberg K: Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumours. Eur J Cancer 1998;34:2046-2052.
9. Liu M, Imam H, Oberg K, Zhou Y: Gene transfer of vasostatin, a calreticulin fragment, into neuroendocrine tumor cells results in enhanced malignant behavior. Neuroendocrinology 2005;82:1-10.
10. Zhou Y, Wang S, Gobl A, Oberg K: Inhibition of CDK2, CDK4 and cyclin E and increased expression of p27Kip1 during treatment with interferon-alpha in carcinoid tumor cells. J Biol Regul Homeost Agents 1999;13:207-215.
11. Mao Y, Schwarzbauer JE: Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol 2005;24:389-399.
12. Mitra SK, Hanson DA, Schlaepfer DD: Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005;6:56-68.
13. Wozniak MA, Modzelewska K, Kwong L, Keely PJ: Focal adhesion regulation of cell behavior. Biochim Biophys Acta 2004;1692:103-119.
14. Morin PJ: Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005;65:9603-9606.
15. Sato N, Fukushima N, Maitra A, Iacobuzio-Donahue CA, van Heek NT, Cameron JL, Yeo CJ, Hruban RH, Goggins M: Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol 2004;164:903-914.
16. Michl P, Barth C, Buchholz M, Lerch MM, Rolke M, Holzmann KH, Menke A, Fensterer H, Giehl K, Lohr M, Leder G, Iwamura T, Adler G, Gress TM: Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 2003;63:6265-6271.
17. Lou Z, O'Reilly S, Liang H, Maher VM, Sleight SD, McCormick JJ: Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 2005;65:1007-1017.
18. Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y, Yao X, Zheng Y, Fan D: Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res 2004;10:6239-6247.
19. Jiang WG, Davies G, Martin TA, Kynaston H, Mason MD, Fodstad O: Com-1/p8 acts as a putative tumour suppressor in prostate cancer. Int J Mol Med 2006;18:981-986.
20. Sun Y, Kim H, Parker M, Stetler-Stevenson WG, Colburn NH: Lack of suppression of tumor cell phenotype by overexpression of TIMP-3 in mouse JB6 tumor cells identification of a transfectant with increased tumorigenicity and invasiveness. Anticancer Res 1996;16:1-7.
21. Yan T, Oberley LW, Zhong W, St Clair DK: Manganese-containing superoxide dismutase overexpression causes phenotypic reversion in SV40-transformed human lung fibroblasts. Cancer Res 1996;56:2864-2871.
22. Zhang Z, Kundu GC, Panda D, Mandal AK, Mantile-Selvaggi G, Peri A, Yuan CJ, Mukherjee AB: Loss of transformed phenotype in cancer cells by overexpression of the uteroglobin gene. Proc Natl Acad Sci USA 1999;96:3963-3968.
23. Xu Y: A new role for p53 in maintaining genetic stability in embryonic stem cells. Cell Cycle 2005;4:363-364.
24. Pluquet O, Hainaut P: Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett 2001;174:1-15.
25. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA: Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol 2004;121:226-230.